Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program

Abstract

Rapamycin demonstrated broad antitumor activity against the PPTP's in vivo tumor panels, with particularly noteworthy activity for selected sarcoma and ALL xenografts. Future work will evaluate the molecular characteristics of responding models and the activity of combinations of rapamycin with other anticancer agents.